Gestational Diabetes

Total Page:16

File Type:pdf, Size:1020Kb

Gestational Diabetes Nutrition PETRY GESTATIONAL DIABETES Origins, Complications, and Treatment DIABETES GESTATIONAL Edited by CLIVE J. PETRY Given the rapid increase in the worldwide incidence of gestational diabetes, the need for defining the risks and effects associated with raised glucose con- centrations in pregnancy is great. Recent large studies are helping to define the risks, as well as identify the benefits of reducing glucose intolerance. Written by an esteemed list of international authors, Gestational Diabetes: Origins, Com- plications, and Treatment presents timely reviews relating to some of the most important aspects of gestational diabetes, specifically its causes, consequences, and treatments. Divided into five sections, the book begins with a section on metabolism in pregnancy and gestational diabetes, dealing with maternal and foetal glucose metabolism and the controversial area of what actually constitutes gestational diabetes. The next section examines risk factors and causes of gestational dia- betes, including the obvious but often overlooked factors—being female and pregnant. The text also outlines environmental and genetic risk factors. The third section deals with the potential complications of gestational diabetes for both mother and offspring, considering short-term and long-term effects. The largest section in the book addresses treatments in an effort to improve the outcome for the mother and the baby. Chapters describe the nutritional approach, considered the cornerstone of treating gestational diabetes, as well as evidence for the role of exercise in its treatment and a useful strategy for treating gestational diabetes pharmacologically. The final section discusses fu- ture prospects in diagnosing and screening, prevention, pathophysiology, and treatment of gestational diabetes. K13753 6000 Broken Sound Parkway, NW Suite 300, Boca Raton, FL 33487 711 Third Avenue an informa business New York, NY 10017 2 Park Square, Milton Park www.taylorandfrancisgroup.com Abingdon, Oxon OX14 4RN, UK CAT#K13753 cover.indd 1 12/13/13 9:38 AM GESTATIONAL DIABETES Origins, Complications, and Treatment Edited by CLIVE J. PETRY GESTATIONAL DIABETES Origins, Complications, and Treatment Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2014 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Version Date: 20131203 International Standard Book Number-13: 978-1-4398-7997-9 (eBook - PDF) This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint. Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmit- ted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright. com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com and the CRC Press Web site at http://www.crcpress.com Contents Preface......................................................................................................................vii About the Editor ........................................................................................................ix Contributors ..............................................................................................................xi SECTION I Gestational Diabetes Chapter 1 Glucose, Foetal Growth, and Pregnancy ..............................................3 Xinhua Chen and Theresa O. Scholl Chapter 2 What Is Gestational Diabetes? ........................................................... 33 Robert Lindsay SECTION II Origins Chapter 3 Environmental Risk Factors for Gestational Diabetes ....................... 51 Eran Hadar and Moshe Hod Chapter 4 Genetic Risk Factors for Gestational Diabetes ..................................69 Clive J. Petry SECTION III Complications Chapter 5 Complications of Gestational Diabetes ..............................................95 Liat Salzer and Yariv Yogev SECTION IV Treatments Chapter 6 Dietary Therapy for Gestational Diabetes ....................................... 119 Colin A. Walsh and Fionnuala M. McAuliffe v © 2010 Taylor & Francis Group, LLC vi Contents Chapter 7 Exercise and Gestational Diabetes ................................................... 147 Michel Boulvain Chapter 8 Pharmacological Treatment of Gestational Diabetes ....................... 157 David Simmons SECTION V Future Prospects Chapter 9 Future Prospects for Gestational Diabetes ....................................... 195 Clive J. Petry © 2010 Taylor & Francis Group, LLC Preface Gestational diabetes, defined as diabetes that first develops in a pregnant woman, is coming of age. Although this has been recognised as a distinct form of diabe- tes since the 1960s, recent large studies such as the Hyperglycemia and Adverse Pregnancy Outcome Study and the Australian Carbohydrate Intolerance Study in Pregnant Women are only now helping to precisely define the risks associated with having raised glucose concentrations in pregnancy, as well as the benefits that may be gained by reducing such glucose intolerance. As such, they may end up making the contribution to gestational diabetes that the Diabetes Control and Complications Trial and the UK Prospective Diabetes Study have made to type 1 and 2 diabetes, respectively. The need for this is great given that the worldwide incidence of gesta- tional diabetes is increasing rapidly in line with the increased prevalence of obesity, and the risks associated with a gestational diabetes pregnancy stretch beyond those to the mother (such as a massively increased risk of developing type 2 diabetes) and the newborn (e.g., macrosomia) to long-term, transgenerational risks in the offspring (such as for obesity and type 2 diabetes, and in females for gestational diabetes). The complications of these transmitted conditions could lead to potentially catastrophic effects, such as the offspring’s generation being the first in modern times to die at younger ages than their parents (Zimmet et al., 2007).* This book therefore sets out to provide timely reviews relating to what may be considered some of the most important aspects of gestational diabetes, in particular its causes, consequences, and ways of treating it. The book is split into five main sec- tions to encompass this. The initial section is based around metabolism in pregnancy and gestational diabetes. The first chapter, by Dr. Chen and Professor Scholl, deals with the important area of maternal and foetal glucose metabolism in pregnancy, particularly in relation to insulin resistance. The second chapter, by Dr. Lindsay, deals with the controversial topic of what actually constitutes gestational diabetes, an area that is currently receiving much attention in the literature. Section II contains chapters about risk factors and causes of gestational diabetes. The most obvious risk factors for gestational diabetes, almost by definition but often overlooked, are the subject being female and pregnant! However, whilst these factors are sensitive for the development of gestational diabetes, they carry no specificity, as only a fraction of pregnant women develop gestational diabetes. Environmental risk factors with greater specificity for gestational diabetes are outlined in Chapter 3 by Dr. Hadar and Professor Hod. In Chapter 4 I then outline the rapidly expanding field of genetic risk factors for gestational diabetes and how these are closely linked to genetic risk factors for other forms of diabetes. Having outlined the causes of gestational diabetes, the succeeding section then deals with the consequences of having this condition, namely, the potential * Zimmet, P. et al. 2007. The International Diabetes Federation Consensus Definition of the Metabolic Syndrome in Children and Adolescents. Brussels, Belgium: IDF Communications. Available at http:// www.idf.org/webdata/docs/Mets_definition_children.pdf. vii © 2010 Taylor & Francis Group, LLC viii Preface complications for both the mother and her offspring. In Chapter 5 Dr. Salzer and Professor Yogev outline
Recommended publications
  • Therapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes
    24 Dec 2005 16:24 AR ANRV262-ME57-17.tex XMLPublishSM(2004/02/24) P1: OJO 10.1146/annurev.med.57.110104.115624 Annu. Rev. Med. 2006. 57:265–81 doi: 10.1146/annurev.med.57.110104.115624 Copyright c 2006 by Annual Reviews. All rights reserved THERAPEUTIC APPROACHES TO PRESERVE ISLET MASS IN TYPE 2DIABETES Laurie L. Baggio and Daniel J. Drucker Department of Medicine, Toronto General Hospital, Banting and Best Diabetes Center, University of Toronto, Toronto, Ontario, Canada M5S 2S2; email: [email protected] KeyWords β-cell mass, apoptosis, neogenesis, proliferation ■ Abstract Type 2 diabetes is characterized by hyperglycemia resulting from in- sulin resistance in the setting of inadequate β-cell compensation. Currently available therapeutic agents lower blood glucose through multiple mechanisms but do not directly reverse the decline in β-cell mass. Glucagon-like peptide-1 (GLP-1) receptor agonists, exemplified by Exenatide (exendin-4), not only acutely lower blood glucose but also engage signaling pathways in the islet β-cell that lead to stimulation of β-cell repli- cation and inhibition of β-cell apoptosis. Similarly, glucose-dependent insulinotropic polypeptide (GIP) receptor activation stimulates insulin secretion, enhances β-cell proliferation, and reduces apoptosis. Moreover, potentiation of the endogenous post- prandial levels of GLP-1 and GIP via inhibition of dipeptidyl peptidase-IV (DPP-IV) also expands β-cell mass via related mechanisms. The thiazolidinediones (TZDs) en- hance insulin sensitivity, reduce blood glucose levels, and also preserve β-cell mass, although it remains unclear whether TZDs affect β-cell mass via direct mechanisms. Complementary approaches to regeneration of β-cell mass involve combinations of factors, exemplified by epidermal growth factor and gastrin, which promote islet neo- genesis and ameliorate diabetes in rodent studies.
    [Show full text]
  • Interleukin 6 Inhibits Mouse Placental Lactogen II but Not Mouse Placental Lactogen I Secretion in Vitro (Trophoblast/Pregnancy/Cytokine) M
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 11905-11909, December 1993 Physiology Interleukin 6 inhibits mouse placental lactogen II but not mouse placental lactogen I secretion in vitro (trophoblast/pregnancy/cytokine) M. YAMAGUCHI*t, L. OGREN*, J. N. SOUTHARD*, H. KURACHI*, A. MIYAKEt, AND F. TALAMANTES*§ *Department of Biology, University of California, Santa Cruz, CA 95064; and tDepartment of Obstetrics and Gynecology, Osaka University Medical School, Osaka, Japan 565 Communicated by George E. Seidel, Jr., September 7, 1993 (receivedfor review June 9, 1993) ABSTRACT The mouse placenta produces several poly- members ofthe PRL-GH gene family. We have used primary peptides belonging to the prolactin-growth hormone gene fam- cultures of placental cells from several days of pregnancy to ily, including mouse placental lactogen (mPL) I and mPL-II. demonstrate that IL-6 regulates the secretion of mPL-II, but The present study was undertaken to determine whether the not mPL-I, and that the sensitivity of mPL-II secretion to secretion of mPL-I and mPL-H is regulated by interleukin 6 IL-6 varies during gestation. (IL-6), which is present in the placenta and has previously been reported to stimulate the secretion ofpituitary members of this gene family. Effects of human and mouse IL-6 on mPL-I and MATERIALS AND METHODS mPL-II secretion were examined in primary cultures of pla- Hormones, Cytokines, and Antisera. mPL-II and recombi- cental cells from days 7, 9, and 12 of pregnancy. IL-6 caused nant mPL-I were purified as described (10, 16). Rabbit a dose-dependent reduction in the mPL-HI concentration in the anti-mPL-I and rabbit anti-mPL-II antisera have been de- medium of cells from days 9 and 12 of pregnancy but did not scribed (11, 16).
    [Show full text]
  • Placental Growth Hormone-Related Proteins and Prolactin-Related Proteins
    Placental Growth Hormone-Related Proteins and Prolactin-Related Proteins The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Haig, D. 2008. Placental growth hormone-related proteins and prolactin-related proteins. Placenta 29: 36-41. Published Version doi:10.1016/j.placenta.2007.09.010 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11148777 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Placental growth hormone-related proteins and prolactin-related proteins. David Haig Department of Organismic and Evolutionary Biology, Harvard University, 26 Oxford Street, Cambridge MA 02138. e-mail: [email protected] phone: 617-496-5125 fax: 617-495-5667 Keywords: GH, PRL, placenta, endometrial glands, placental lactogen The placentas of ruminants and muroid rodents express prolactin (PRL)-related genes whereas the placentas of anthropoid primates express growth hormone (GH)-related genes. The evolution of placental expression is associated with acclerated evolution of the corresponding pituitary hormone and destabilization of conserved endocrine systems. In particular, placental hormones often evolve novel interactions with new receptors. The adaptive functions of some placental hormones may be revealed only under conditions of physiological stress. Introduction Placental hormones are produced by offspring, but act on receptors of mothers. As such, placental hormones and maternal receptors are prime candidates for the expression of parent-offspring conflict [1,2].
    [Show full text]
  • The Importance of Determining Human
    JMB 2009; 28 (2) DOI: 10.2478/v10011-009-0003-1 UDK 577.1 : 61 ISSN 1452-8258 JMB 28: 97–100, 2009 Original paper Originalni nau~ni rad THE IMPORTANCE OF DETERMINING HUMAN PLACENTAL LACTOGEN IN THE THIRD TRIMESTER OF PREGNANCY ZNA^AJ ODRE\IVANJA HUMANOG PLACENTALNOG LAKTOGENA U TRE]EM TRIMESTRU TRUDNO]E Jasmina Durkovi}1, Bojana Mandi}2 1Department of Genetics , Town Hospital, Subotica, Serbia 2Mega Lab, Biochemical Laboratory, Subotica, Serbia Summary: Human placental lactogen (HPL) is a hormone Kratak sadr`aj: Humani placentalni laktogen (HPL) jeste produced by the placenta with a role in the re gu lation of hormon koji izlu~uje placenta i regulator je fetoplacen- fetoplacental growth. In this paper, the results of HPL de- talnog rasta. U radu su prikazani rezultati odre|ivanja HPL- termination in the third trimester of pregnancy are pre- a u tre}em trimestru trudno}e, sa ciljem da se ispita senzi - sented with the aim of testing the sensitivity of this bio - tivnost tog biohemijskog markera za otkrivanje poreme}aja chemical marker for detecting placental dysfunction, fetal funkcije placente, vitaliteta fetusa i rizika za lo{ ishod. vitality and risk of bad outcome. The tests were performed Ispitivanje je obavljeno na uzorku od 370 rizi~nih trudno}a on 370 women with high-risk pregnancy, between the 20th izme|u 20 i 36 nedelje trudno}e. HPL je odre|en ELISA and 36th week of pregnancy. HPL was determined by an metodom, testovima »Bioserv Diagnostics«, a rezultati su ELISA method using Bioserv Diagnostics tests and the o~itani na rideru »STAT–FAX 303+«.
    [Show full text]
  • The Endocrine Function of the Placenta: Interactions Between Trophic Peptides and Hormones
    Placenlal Function and Fetal Nutrition, edited by Frederick C. Battaglia, Nestle Nutrition Workshop Series. Vol. 39. Nestec Ltd.. Vevey/Lippincott-Raven Publishers. Philadelphia. © 1997. The Endocrine Function of the Placenta: Interactions Between Trophic Peptides and Hormones Lise Cedard U. 361 INSERM, Maternite Baudelocque, 121 Boulevard de Port-Royal Paris, France The placenta is classically considered to be a source of hormones that play an important role in the establishment and maintenance of pregnancy. Because of its hemochorial structure, the human placenta produces hormones and easily secretes them into the maternal circulation. They include steroid hormones, such as estrogens and progesterone, and protein hormones, the most important of which are the chori- onic gonadotrophins (hCG), discovered in 1927. During the period from 1960 to 1980, the concept of a fetoplacental unit (1) with a complementary role for the fetus in steroid production offered a new approach to steroid metabolism, and since then new proteins and neuropeptides have been discovered (2,3). However, the lack of innervation of placental tissue highlights the importance of understanding neuroen- docrine regulation of placental physiology. Sophisticated culture methods enabling the study of biologic phenomena occurring during transformation of cytotrophoblast cells into a syncytiotrophoblast (4) have been combined with electron microscopy and histochemistry. Possibilities offered by molecular biology, including in situ hybridization and molecular cloning studies,
    [Show full text]
  • Hormonal Regulation of Fetal Growth
    Inrntuterine Growth Reianlaliim, edited by Jacques Senterre. Nestle Nutrition Workshop Scries, Vol. 18. Nestec Ltd.. Vevey/Raven Press. Ltd., New York © 1989. Hormonal Regulation of Fetal Growth Jean Girard Centre de Recherche sur la Nutrition (CNRS), 92190 Meudon-Bellevue, France The regulation of fetal growth is complex and still very poorly understood. It in- volves genetic factors, maternal nutrition and cardiovascular adaptations, placental growth and function, and to a lesser extent fetal factors, including fetal hormones. The influence of genetic, maternal, and placental factors on fetal growth has been reviewed recently (1) and will not be discussed. The purpose of this chapter is to analyze the specific role of endocrine factors in the determination of fetal growth, assuming that the nutritional supply to the placenta and to the fetus remains un- altered. The major endocrine factors involved in postnatal growth are: (a) growth hor- mone (GH) via the secretion of somatomedin; (b) thyroid hormones; (c) cortisol; and (d) sex steroids at puberty (2,3). Insulin is considered to have a merely permis- sive role in postnatal growth (2,3). In recent years, a body of evidence has accumu- lated to indicate that the fetus may be less dependent on pituitary and thyroid hormones for growth than the older organism, and more dependent on insulin and tissue growth factors. Studies on the endocrine regulation of fetal growth have in- volved several major approaches: ablation of fetal endocrine glands; examination of newborns with congenital endocrine deficiencies; treatment of fetuses with hor- mones; measurement of plasma hormone concentrations and tissue receptor levels during normal or abnormal growth; and in vitro studies of hormone effects on fetal tissues.
    [Show full text]
  • A Role for Placental Kisspeptin in Β Cell Adaptation to Pregnancy
    A role for placental kisspeptin in β cell adaptation to pregnancy James E. Bowe, … , Stephanie A. Amiel, Peter M. Jones JCI Insight. 2019;4(20):e124540. https://doi.org/10.1172/jci.insight.124540. Research Article Endocrinology Reproductive biology During pregnancy the maternal pancreatic islets of Langerhans undergo adaptive changes to compensate for gestational insulin resistance. Kisspeptin has been shown to stimulate insulin release, through its receptor, GPR54. The placenta releases high levels of kisspeptin into the maternal circulation, suggesting a role in modulating the islet adaptation to pregnancy. In the present study we show that pharmacological blockade of endogenous kisspeptin in pregnant mice resulted in impaired glucose homeostasis. This glucose intolerance was due to a reduced insulin response to glucose as opposed to any effect on insulin sensitivity. A β cell–specific GPR54-knockdown mouse line was found to exhibit glucose intolerance during pregnancy, with no phenotype observed outside of pregnancy. Furthermore, in pregnant women circulating kisspeptin levels significantly correlated with insulin responses to oral glucose challenge and were significantly lower in women with gestational diabetes (GDM) compared with those without GDM. Thus, kisspeptin represents a placental signal that plays a physiological role in the islet adaptation to pregnancy, maintaining maternal glucose homeostasis by acting through the β cell GPR54 receptor. Our data suggest reduced placental kisspeptin production, with consequent impaired kisspeptin-dependent β cell compensation, may be a factor in the development of GDM in humans. Find the latest version: https://jci.me/124540/pdf RESEARCH ARTICLE A role for placental kisspeptin in β cell adaptation to pregnancy James E.
    [Show full text]
  • Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
    nutrients Review Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases João V. S. Guerra 1,2,† , Marieli M. G. Dias 1,3,† , Anna J. V. C. Brilhante 3,4, Maiara F. Terra 1,3, Marta García-Arévalo 1,* and Ana Carolina M. Figueira 1,* 1 Brazilian Center for Research in Energy and Materials (CNPEM), Brazilian Biosciences National Laboratory (LNBio), Polo II de Alta Tecnologia—R. Giuseppe Máximo Scolfaro, Campinas 13083-100, Brazil; [email protected] (J.V.S.G.); [email protected] (M.M.G.D.); [email protected] (M.F.T.) 2 Graduate Program in Pharmaceutical Sciences, Faculty Pharmaceutical Sciences, University of Campinas, Campinas 13083-970, Brazil 3 Graduate Program in Functional and Molecular Biology, Institute of Biology, State University of Campinas (Unicamp), Campinas 13083-970, Brazil; [email protected] 4 Brazilian Center for Research in Energy and Materials (CNPEM), Brazilian Biorenewables National Laboratory (LNBR), Polo II de Alta Tecnologia—R. Giuseppe Máximo Scolfaro, Campinas 13083-100, Brazil * Correspondence: [email protected] or [email protected] (M.G.-A.); ana.fi[email protected] (A.C.M.F.) † Both authors contributed equally to this work. Abstract: Throughout the 20th and 21st centuries, the incidence of non-communicable diseases (NCDs), also known as chronic diseases, has been increasing worldwide. Changes in dietary and physical activity patterns, along with genetic conditions, are the main factors that modulate the Citation: Guerra, J.V.S.; Dias, metabolism of individuals, leading to the development of NCDs. Obesity, diabetes, metabolic M.M.G.; Brilhante, A.J.V.C.; Terra, associated fatty liver disease (MAFLD), and cardiovascular diseases (CVDs) are classified in this M.F.; García-Arévalo, M.; Figueira, group of chronic diseases.
    [Show full text]
  • Preoptic Inputs and Mechanisms That Regulate Maternal Responsiveness
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Repository of the Academy's Library Received Date : 14-Jan-2014 Revised Date : 21-Jul-2014 Accepted Date : 22-Jul-2014 Article type : Review Article Preoptic inputs and mechanisms that regulate maternal responsiveness A. Dobolyi1,2, D.R. Grattan3, D. S. Stolzenberg4 1Laboratory of Molecular and Systems Neurobiology, Institute of Biology, NAP-Hungarian Academy of Sciences and Eötvös Loránd University, Budapest, Hungary 2Laboratory of Neuromorphology, Department of Anatomy, Histology and Embryology, Article Semmelweis University, Budapest, Hungary 3Department of Anatomy and Centre for Neuroendocrinology, School of Medical Sciences, University of Otago, Dunedin, New Zealand 4Department of Psychology, University of California, David CA, USA Corresponding Authors: Prof. Arpad Dobolyi, Laboratory of Molecular and Systems Neurobiology, Institute of Biology, Eötvös Loránd University, Pázmány Péter sétány 1C, Budapest 1117, Hungary email: [email protected] Danielle S. Stolzenberg, Department of Psychology, 135 Young Hall, University of California Davis, CA 95616, USA Email: [email protected] Short title: Preoptic mechanisms of maternal responsiveness Key words: maternal motivation, and maternal behaviour, medial preoptic area of hypothalamus, epigenetics, postpartum period This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to Accepted differences between this version and the Version of Record. Please cite this article as doi: 10.1111/jne.12185 This article is protected by copyright. All rights reserved. Abstract The preoptic area is a well-established centre for the control of maternal behaviour.
    [Show full text]
  • Human Placental Lactogen Administration in the Pregnant Rat: Acceleration of Fetal Growth
    003 1-399818812406-0663$02.00/0 PEDIATRIC RESEARCH Vol. 24, No. 6, 1988 Copyright O 1988 International Pediatric Research Foundation, Inc. Printed in U.S.A. Human Placental Lactogen Administration in the Pregnant Rat: Acceleration of Fetal Growth JAMES W. COLLINS, JR., SANDRA L. FINLEY, DANIEL MERRICK, AND EDWARD S. OGATA Departments of Pediatrics, Obstetrics and Gynecology, Northwestern University Medical School and Prentice Women's Hospital of Northwestern Memorial Hospital and Children's Memorial Hospital, Chicago, Illinois 60611 ABSTRACT. To determine whether administration of hu- servations suggest that placental lactogen may also directly stim- man placental lactogen (hPL) to pregnant rats during late ulate fetal growth. Ovine placental lactogen stimulates glycoge- gestation might enhance fetal growth, we implanted os- nesis in hepatocytes of the fetal rat (4) and sheep (5) and motically driven minipumps to provide 75 pg h PL/24 h on aminoisobutyric acid uptake in diaphragmatic muscle of the fetal day 14 of the rat's 21.5-day gestation. This substantially rat (6). It also stimulates ornithine decarboxylase activity in fetal increased maternal and fetal plasma hPL concentrations. rat liver (7) and somatomedin secretion in fetal and adult tissue By day 18, hPL fetuses were significantly heavier and had (8-10). Handwerger (11) has suggested that these and other larger placentas than controls. From this point until term, observations indicate a critical role for placental lactogen in not their rate of growth (1.20 g/24 h) significantly exceeded only indirectly but also directly stimulating normal fetal growth that of controls (0.95 g/24 h).
    [Show full text]
  • Placental Lactogen-I (PL-I) Target Tissues Identified with an Alkaline Phosphatase–PL-I Fusion Protein
    Volume 46(6): 737–743, 1998 The Journal of Histochemistry & Cytochemistry http://www.jhc.org ARTICLE Placental Lactogen-I (PL-I) Target Tissues Identified with an Alkaline Phosphatase–PL-I Fusion Protein Heiner Müller,1 Guoli Dai, and Michael J. Soares Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, Kansas SUMMARY The rat placenta expresses a family of genes related to prolactin (PRL). Target tissues and physiological roles for many members of the PRL family have yet to be deter- mined. In this investigation we evaluated the use of an alkaline phosphatase (AP) tag for monitoring the behavior of a prototypical member of the PRL family, placental lactogen-I (PL-I). A probe was generated consisting of a fusion protein of human placental AP and rat KEY WORDS PL-I (AP–PL-I). The AP–PL-I construct was stably expressed in 293 human fetal kidney cells, as alkaline phosphatase fusion was the unmodified AP vector that served as a control. AP activity was monitored with a protein colorimetric assay in conditioned medium from transfected cells. Immunoreactivity and ovary, corpus luteum prolactin PRL-like biological activities of the AP–PL-I fusion protein were demonstrated by immuno- receptors blotting and the Nb2 lymphoma cell proliferation assay, respectively. AP–PL-I specifically liver, hepatic prolactin bound to tissue sections known to express the PRL receptor, including the ovary, liver, and receptors choroid plexus. Binding of AP–PL-I to tissues was specific and could be competed with ovine Nb2 lymphoma cells PRL. The results indicate that AP is an effective tag for monitoring the behavior of PL-I and placental lactogen-I suggest that this labeling system may also be useful for monitoring the actions of other pregnancy members of the PRL family.
    [Show full text]
  • Hormones Steroids Antibodies
    Fitzgerald Industries International is the premier provider of over 45,000 highly purified Monoclonal and Polyclonal Antibodies, purified Proteins, ELISA Kits and Specialty Research Products. For more than 20 years our customers have known that they can depend on Fitzgerald Industries to supply them with high quality products for research and further manufacture. Hormones and their receptors play a central role in the regulation of gene expression. These soluble receptors, when bound to their corresponding hormone, regulate gene expression through direct interaction with promoter response elements. Fitzgerald Industries offers a wide selection of tools that can be used to investigate the function of hormones and their receptors, and our current brochure encompasses over 800 antibodies and purified hormones and steroids spanning a vast range of targets including steroid hormones such as Glucocorticoids, Estrogens, Androgens; small peptide hormones such as TRH and vasopressin; protein hormones such as insulin and growth hormones; and glycoprotein hormones such as LH, TSH, and FSH. In addition, we offer comprehensive listings in other research areas including Cancer, Cell Biology, Immunology, Infectious Disease, Signal Transduction, Neuroscience, Cytokines & Growth Factors, Cardiac Markers, Protein Modification, Cell Death & Stress, and many more. Visit our website at www.fitzgerald-fii.com to view our complete offerings and full technical data. www.fitzgerald-fii.com/Hormones & Steroids Hormones & Steroids 1 Fitzgerald Industries International
    [Show full text]